Albumin and eGFR baseline were statistically (but not clinically relevant) significantly higher in head and neck cancer patients (median: 42 vs. 41 mmol/L; 94.3 vs. 92.2 mL/min/1.73 m2, respectively). This evidence concerns the gene ALB and head and neck cancer.